011_Sequence Listing.ST25.txt
SEQUENCE LISTING

<110> Hermida Santos, José
       Montes Díaz, Ramón
       Hurtado Linares, Verónica

<120> METHOD FOR ASSESSING RISK OF AND PREDISPOSITION TO DEVELOPMENT OF
       A PATHOLOGY RELATED TO THE PRESENCE OF ANTI-EPCR AUTOANTIBODIES

<130> 020884-000011

<140> Not yet assigned
<141> 2006-08-04

<150> PCT/ES2005/000046
<151> 2005-02-03

<150> P200400269
<151> 2004-02-06

<160> 6

<170> PatentIn version 3.3

<210> 1
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 1
agcttggcat atcgattagc caagacgcct cagatg   36

<210> 2
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 2
tattctatgc ggccgccgaa gtgtaggagc ggcttg   36

<210> 3
<211> 222
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 3

Ser Ile Ser Gln Asp Ala Ser Asp Gly Leu Gln Arg Leu His Met Leu
1   5   10   15

Gln Ile Ser Tyr Phe Arg Asp Pro Tyr His Val Trp Tyr Gln Gly Asn
            20   25   30

Ala Ser Leu Gly Gly His Leu Thr His Val Leu Glu Gly Pro Asp Thr

```
                  35                40                45
```

```
Asn Thr Thr Ile Ile Gln Leu Gln Pro Leu Gln Glu Pro Glu Ser Trp
    50                55                60
```

```
Ala Arg Thr Gln Ser Gly Leu Gln Ser Tyr Leu Leu Gln Phe His Gly
65                70                75                80
```

```
Leu Val Arg Leu Val His Gln Glu Arg Thr Leu Ala Phe Pro Leu Thr
                85                90                95
```

```
Ile Arg Cys Phe Leu Gly Cys Glu Leu Pro Pro Glu Gly Ser Arg Ala
            100               105               110
```

```
His Val Phe Phe Glu Val Ala Val Asn Gly Ser Ser Phe Val Ser Phe
            115               120               125
```

```
Arg Pro Glu Arg Ala Leu Trp Gln Ala Asp Thr Gln Val Thr Ser Gly
    130               135               140
```

```
Val Val Thr Phe Thr Leu Gln Gln Leu Asn Ala Tyr Asn Arg Thr Arg
145               150               155               160
```

```
Tyr Glu Leu Arg Glu Phe Leu Glu Asp Thr Cys Val Gln Tyr Val Gln
            165               170               175
```

```
Lys His Ile Ser Ala Glu Asn Thr Lys Gly Ser Gln Thr Ser Arg Ser
            180               185               190
```

```
Tyr Thr Ser Ala Ala Ala Ser Phe Leu Glu Gln Lys Leu Ile Ser Glu
    195               200               205
```

```
Glu Asp Leu Asn Ser Ala Val Asp His His His His His His
    210               215               220
```

```
<210>   4
<211>   6
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic Construct

<400>   4

Ala His Gly His Arg Pro
1               5


<210>   5
<211>   14
<212>   PRT
<213>   Artificial Sequence

<220>
```

<223> Synthetic Construct

<400> 5

Pro Ile His Asp His Asp His Pro His Leu Val Ile His Ser
1   5   10

<210> 6
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> X may be any essential amino acid

<400> 6

Gly Met Thr Cys Xaa Xaa Cys
1   5